# A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

> **NCT04814615** · PHASE2 · UNKNOWN · sponsor: **Hoag Memorial Hospital Presbyterian** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** 89Zr-daratumumab PET/CT

## Key facts

- **NCT ID:** NCT04814615
- **Lead sponsor:** Hoag Memorial Hospital Presbyterian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-08
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-03-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814615, "A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04814615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*